Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansa Biopharma AB ( (SE:HNSA) ) has issued an announcement.
Hansa Biopharma has increased its registered share capital and the number of shares and votes by issuing 17,000,000 new ordinary shares, bringing the total to 101,763,222 shares and votes. This move reflects the company’s strategic efforts to strengthen its financial position and support its ongoing research and development initiatives in the biopharmaceutical industry.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK32.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for kidney transplantation, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 644,133
Technical Sentiment Signal: Hold
Current Market Cap: SEK3.12B
For detailed information about HNSA stock, go to TipRanks’ Stock Analysis page.